NEWS FAQ INVESTORS WHY WE EXIST PIPELINE THE PAIN TRUTH ABOUT PAD OUR COMPANY FOLLOW THE PROGRESS Investor Relations Overview News & Events Company Info FAQ Financial Info Stock Data SEC Filings Governance Contact Us Latest News SEP 28, 2021 JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101 View Press Release JUL 22, 2021 JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients JUN 23, 2021 JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites View All News Latest Presentation Investor Presentation (August 2020) View Presentation Recent Event NOV 2, 2021 10:00 AM PST 2021 Annual Meeting of Stockholders View All Latest Financial Results Q3 2021 QUARTER ENDED OCT 2, 2021 10-Q Filing PDF HTML XBRL ZIP XLS HTML Latest Annual Filing For Fiscal Year Ending Jan 2, 2021 Report Links Annual Report Document Links VIEW 10-K Sign Up For Email Alerts Receive updates straight into your inbox SIGN UP TODAY Company Overview JanOne (NASDAQ: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease ("PAD"), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives. VIEW MANAGEMENT TEAM VIEW BOARD OF DIRECTORS Investor Contact Information Company JanOne Inc. 325 E. Warm Springs Road Suite 102 Las Vegas, NV 89119 Email Alerts Tear Sheet Contacts RSS News Feed JanOne is a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. As a result, we hope to reduce the need for prescribing dangerous opioid drugs. Our first drug candidate is a treatment for Peripheral Arterial Disease (PAD), a condition that can cause severe pain and affects over 8.5 million people in the US alone. The company trades under the symbol JAN on the NASDAQ and continues to independently operate its subsidiary business – Appliance Recycling Centers of America, Inc (ARCA). Latest News JanOne on Twitter Why We Exist Pipeline The Pain Truth About PAD Our Company News FAQs Investors Contact Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.